Candriam Equities L Biotechnology Class R GBP Cap

Register to Unlock Ratings
Performance History31/10/2024
Growth of 1,000 (GBP) Advanced Graph
Candriam Equities L Biotechnology Class R GBP Cap
Fund16.5-1.011.82.09.7
+/-Cat-9.58.019.63.38.2
+/-B’mrk-16.5-1.39.3-5.33.9
 
Key Stats
NAV
20/11/2024
 GBP 371.66
Day Change 0.87%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN LU1269736911
Fund Size (Mil)
19/11/2024
 USD 1402.40
Share Class Size (Mil)
19/11/2024
 GBP 0.88
Max Initial Charge 3.50%
Ongoing Charge
01/03/2024
  1.11%
Morningstar Research
Analyst Report18/03/2024
Jeffrey Schumacher, Director
Morningstar, Inc

An expanding and highly qualified team led by one of the industry’s most seasoned investors in the field, combined with a proven process give this fund an edge. The fund’s cheapest share classes receive a Morningstar Analyst Rating of Silver,...

Click here to read this analyst report on the underlying fund.
Morningstar Pillars
People24
Parent23
Process24
Performance
Price
Investment Objective: Candriam Equities L Biotechnology Class R GBP Cap
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund.
Returns
Trailing Returns (GBP)20/11/2024
YTD6.60
3 Years Annualised6.40
5 Years Annualised8.05
10 Years Annualised*8.92
12 Month Yield 0.00
Management
Manager Name
Start Date
Linden Thomson
29/02/2024
Rudi Van den Eynde
06/04/2000
Click here to see others
Inception Date
08/03/2016
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  Candriam Equities L Biotechnology Class R GBP Cap30/09/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock96.920.0096.92
Bond0.000.000.00
Property0.000.000.00
Cash3.080.003.08
Other0.000.000.00
Top 5 Regions%
United States78.68
Eurozone8.00
Europe - ex Euro5.55
United Kingdom3.00
Asia - Emerging1.94
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Regeneron Pharmaceuticals IncHealthcareHealthcare6.42
Amgen IncHealthcareHealthcare5.97
Gilead Sciences IncHealthcareHealthcare5.17
Alnylam Pharmaceuticals IncHealthcareHealthcare5.03
Vertex Pharmaceuticals IncHealthcareHealthcare4.82
Candriam Equities L Biotechnology Class R GBP Cap

Related

* This share class has performance data calculated prior to the inception date, 2016-03-08. This is based upon a simulated/extended track record, using the track record of Candriam Eqs L Biotech C USD Cap (ISIN: LU0108459040), and is in accordance with Morningstar’s Extended Performance Methodology paper. To find out more about this, click here.
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures